TickerTalks
Browse all tickers →
TickerTalks›$IQV
IQIQV

IQVIA Holdings Inc.

$IQV·$35B·Medical - Diagnostics & Research·Healthcare
$206.26-2.0%YTD-8.5%1Y+26.3%
Mentions · last 7 days
2026-07-10: 24 posts2026-07-11: 58 posts2026-07-12: 118 posts2026-07-13: 175 posts2026-07-14: 47 posts2026-07-15: 43 posts2026-07-16: 27 posts495+5%
Price updated 58m ago·X counts updated 35m ago
IQIQV
$IQVIQVIA Holdings Inc.
$206.26-2.01%495 posts+5%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $IQV, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersEvent coming upAI verdict · as of 2026-07-17

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

The clinical-research-organization compounder priced as if biopharma R&D isn't recovering — July 28 is the specific test.

IQVIA Holdings is the largest global clinical-research organization — the specific vendor every biopharma company uses to run late-stage trials and post-market surveillance. The stock is 6.6% off year-to-date levels going into July 28 earnings.

Why the setup reads reasonable:

  • Fundamentals are compounder-grade: 14% operating margin, 8.4% return on invested capital, and 8.7% free cash flow yield at 22x TTM P/E — meaning IQV earns quality-industrial economics at a market-average multiple.
  • The tape is quietly turning: sitting 14.5% above the 50-day and 7% above the 200-day, at 60% of the 52-week range — early stages of a repositioning, not late-stage chase.
  • The biopharma R&D backdrop is durable: even if any specific pharma name has soft Q, the aggregate spend on late-stage trials continues to compound with the pipeline — meaning IQV's contracted backlog is the specific durable revenue.
  • The check is bookings sensitivity: any specific biopharma R&D-budget cut lands on IQV's new-bookings line first, so a soft-bookings guide is the specific downside the tape hasn't priced.

July 28 earnings is the trigger. A number confirming new-bookings growth plus stable Q3 commentary extends the leg; a soft bookings print with muted commentary is the specific setup for a compression back to the 200-day.

What to watch: The July 28 print — new-bookings trajectory, contracted backlog growth, and any commentary on biopharma R&D-budget pressures. Above-consensus bookings extend the leg; a soft bookings print activates the compression back to the 200-day.

On the calendar: 2026-07-28 — Q2 earnings

Read the AI verdict + X sentiment for $IQV

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Provides healthcare data analytics, clinical trial management, and technology services to life sciences companies globally.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $IQV.

Medical - Diagnostics & Research · Healthcare

No material change from last week — pharma R&D spending is recovering and CDMO demand is growing as drug pipelines advance toward clinical trials.

What this means for $IQV

Direct beneficiary — Provides healthcare data analytics, clinical trial management, and technology services to life sciences companies globally; core operations sit in the path of the pharma R&D recovery and CDMO outsourcing demand expansion.

Industry benchmark

13-name peer basket
+36.4%YTD
+70.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
22.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
8.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
13.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
8.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
22.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
26.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 5, 2026$2.90$2.82+2.8%
Q4 2025Feb 5, 2026$3.42$3.40+0.6%
Q3 2025Oct 28, 2025$3.00$2.98+0.7%
Q2 2025Jul 22, 2025$2.81$2.77+1.4%
Next earningsTue, Jul 28·consensus EPS $3.03

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$4.2B+8.4%32.6%12.4%$1.63$618.0M
Q4 FY25$4.4B+10.3%6.7%16.8%$3.02$561.0M
Q3 FY25$4.1B+5.2%33.5%13.5%$1.94$1.2B
Q2 FY25$4.0B+5.3%32.9%12.6%$1.55$292.0M

Forward consensus

5-year forecast · up to 15 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$17.3B$17.2B – $17.4B$12.82$12.70 – $12.9215
FY27$18.3B$18.0B – $18.8B$14.15$13.61 – $14.7215
FY28$19.2B$19.2B – $19.3B$15.70$13.65 – $18.5114
FY29$20.4B$20.2B – $20.8B$17.68$17.48 – $18.139
FY30$21.5B$21.3B – $21.9B$19.61$19.39 – $20.1113

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.60%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+14.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+7.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 158.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.205-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 53 other (39 awards · 14 inkinds) in window

See when $IQV insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJun 118-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation
AI summary

IQVIA Inc. (a wholly owned subsidiary of IQVIA Holdings Inc.) completed the issuance of €950 million (~$1.04B) in 4.625% senior unsecured notes due June 15, 2033, on June 11, 2026. The notes are guaranteed by certain IQVIA subsidiaries; interest is payable semi-annually beginning December 15, 2026. Net proceeds will be used to refinance existing indebtedness and pay transaction fees. This is a euro-denominated refinancing that extends IQVIA's debt maturity profile at a moderate fixed rate, consistent with prior capital-structure management for a large healthcare data and analytics company.

8-KOfficer or director changeApr 238-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

IQV disclosed a personnel change (8-K Item 5.02, dated 2026-04-23). An executive departure and a new appointment are both reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

+ 13 other (3 routine 8-Ks · 2 earnings 8-Ks · 2 13Gs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

IQV vs. PEN: Which Stock Is the Better Value Option?zacks.com·3d agoHere's Why IQVIA Holdings (IQV) is a Strong Value Stockzacks.com·9d agoHere's Why Investors Should Hold IQV Stock in Their Portfolios Nowzacks.com·15d agoStackAdapt Teams Up with IQVIA Digital's MediaOS to Power Healthcare Advertisingbusinesswire.com·30d agoThe Healthcare M&A Waveforbes.com·30d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight LossAI Precision Medicine

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TMO$DHR$A$ILMN$NTRA$TWST$STIM$CDNA
Voices on X · last 7 days

No standout posts about $IQV on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport